Teva Pharmaceutical Industries Limited - ADR earnings per share and revenue
On Jan 28, 2026, TEVA reported earnings of 0.96 USD per share (EPS) for Q4 25, beating the estimate of 0.69 USD, resulting in a 38.55% surprise. Revenue reached 4.71 billion, compared to an expected 4.46 billion, with a 5.74% difference. The market reacted with a +2.09% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 4 analysts forecast an EPS of 0.51 USD, with revenue projected to reach 3.90 billion USD, implying an decrease of -46.88% EPS, and decrease of -17.20% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Dr. Reddy's Laboratories Limited - ADR
Report Date
Jan 21, 2026 For Q3 26
Estimate
$13.86
Actual
$14.52
Surprise
+4.69%
FAQ
What were Teva Pharmaceutical Industries Limited - ADR's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Teva Pharmaceutical Industries Limited - ADR reported EPS of $0.96, beating estimates by 38.55%, and revenue of $4.71B, 5.74% above expectations.
How did the market react to Teva Pharmaceutical Industries Limited - ADR's Q4 2025 earnings?
The stock price moved up 2.09%, changed from $32.53 before the earnings release to $33.21 the day after.
When is Teva Pharmaceutical Industries Limited - ADR expected to report next?
The next earning report is scheduled for May 05, 2026.
What are the forecasts for Teva Pharmaceutical Industries Limited - ADR's next earnings report?
Based on 4
analysts, Teva Pharmaceutical Industries Limited - ADR is expected to report EPS of $0.51 and revenue of $3.90B for Q1 2026.